Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

NEW ORLEANS, Dec. 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today an abstract to be published online at the journal Blood website by M. Hacker, et al. demonstrating significant reduction in cardiac cell toxicity with pixantrone compared to currently marketed anthracyclines. The authors conclude that the reduction is due to pixantrone's inability to generate toxic drug iron complexes and reduced propensity to generate oxygen free radicals. Pixantrone was specifically designed to have a higher affinity and avidity for the topisomerase II enzyme, which is the common target for this class of anti-cancer agents, while reducing oxygen-free radicals and preventing the formation of toxic drug metal complexes, which are the primary culprit that leads to dose-related irreversible heart damage associated with standard anthracyclines.

"This study adds to the growing scientific evidence which is central to the mechanistic basis for the relatively low incidence of cardiac events observed in our pixantrone clinical trials compared to the expected incidence of events had other anthracyclines been used. The ability to reintroduce an effective anthracycline like agent to patients who are no longer eligible to receive further standard anthracycline therapy due to potential irreversible heart damage addresses a major and growing unmet medical need," Jack Singer, M.D., Chief Medical Officer of Cell Therapeutics, Inc.

About the Study

To validate the proposed mechanisms underlying the observed differences in cardiotoxicity, researchers used established spectrophotometric techniques to quantify iron and drug interactions that are thought to be mechanistic for chronic doxorubicin cardiotoxicity. When adding increasing amounts of iron to drug solutions, they observed that doxorubicin and mitoxantrone underwent changes in visible range absorbance patterns, which is charact
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Report Details   ... you trends, R&D progress, and predicted revenues ,Where is ... are the commercial prospects for this market and related ... and other trends to 2025, discussing data, opportunities and ... assess regenerative medicine : cell-based therapies that aim ...
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)... 2015  Two mass spectrometry technologies MALDI ... their effectiveness is established, according to biotechnology ... says that while mass spectrometry (mass spec ... in proteomic biomarker discovery and validation, mass ... techniques has struggled to elucidate molecular distribution ...
Breaking Medicine Technology:Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3
... ATHENS, Greece , July 9 The ... licensee and translator of the Greek language version of the ... complete the program will include hundreds of drugs used exclusively ... a Greek language graphical user interface. Both the English and ...
... , MUNDELEIN, Ill. , July 8 ... diagnostic testing equipment and information systems technology, today ... with Amerinet.  Amerinet members have immediate purchasing/leasing access ... and service.  Training and technical support for Amerinet ...
Cached Medicine Technology:Medigene Appointed Exclusive Greek Licensee for GeneMedRx Personalized Prescribing Software 2Sysmex America Announces Amerinet Urinalysis Contract 2Sysmex America Announces Amerinet Urinalysis Contract 3
(Date:2/28/2015)... NY (PRWEB) February 28, 2015 On Thursday, ... Kits Make It Easy For Scammers To Steal Your Data ... can get their hands on a DIY phishing kit, or ... it also touched on another important point about how everyone’s ... kits are often implemented, “like compromising legitimate content management systems ...
(Date:2/28/2015)... February 28, 2015 Javon Bea ... Mercy Harvard Hospital as stroke capable by the State ... via ambulance to Mercy Harvard Hospital. , The hospital ... indicate their ability to treat stroke according to national ... ambulances transporting stroke patients to bypass hospitals not designated ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The World ... and learning materials to potential EMTs and firefighters, recently ... Bitcoins as a way to raise charitable donations for ... in Medellin, Columbia, will be held on March 29, ... run will begin at 3:30 p.m. , To ...
(Date:2/27/2015)... Wireless Analytics, an award-winning provider ... the founders of the wireless expense management ... their CLEAN Platform™ (Communications Lifecycle Expense Analytics) mobility ... developed Bell Mobility Data Loader enables unprecedented enterprise-wide ... business customers. , Wireless Analytics cites customer demand ...
(Date:2/27/2015)... February 27, 2015 Those ... are often misunderstood, misdiagnosed and therefore aren’t ... healthy lives. Jacksonville-based addiction treatment center ... its highly acclaimed Lakeview Professional Lecture Series ... in understanding this complicated condition. ...
Breaking Medicine News(10 mins):Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2
... , , , , , ... - The prize With a EUR 3,000 ... First Time on 31 October 2010 . , ... Clinic,DDr. Heinrich for outstanding reporting on New Cosmetic Surgery techniques. , ...
... conducted at 100 centers worldwide indicate that belatacept, a ... new organs. The results also suggest that it may ... with fewer side effects and superior kidney function after ... American Journal of Transplantation , provides the first ...
... , ... Cumulative Spending Figures , ... DC (PRWEB) Feb. 17, 2010 -- A one-year scorecard on the American Recovery and Reinvestment ... the way for huge impacts in 2010. Onvia is the leader in business-to-government solutions ...
... that emphasizes social behaviors, , WEDNESDAY, Feb. 17 (HealthDay News) ... in infants before they,re 6 months old but do start ... year. , "This study tells us that screening for ... not going to be successful because there isn,t going to ...
... , Feb. 17 MedCath Corporation (Nasdaq: ... have entered into a definitive agreement to sell substantially all ... Healthcare Partnership, L.P. ("St. David,s"). The transaction is expected to ... customary closing conditions and regulatory requirements. , The sale comes ...
... ... disease that kills thousands each year. , ... New York, NY (PRWEB) February 17, 2010 -- A leading attorney for ... up its spending on research into new ways to treat the fatal disease caused by ...
Cached Medicine News:Health News:"New Cosmetic Surgery" Journalism Prize 2Health News:New drug for kidney transplant recipients effective in humans 2Health News:Recovery Act's One Year Anniversary -- 2009 Was Just the Opening Act 2Health News:Recovery Act's One Year Anniversary -- 2009 Was Just the Opening Act 3Health News:Recovery Act's One Year Anniversary -- 2009 Was Just the Opening Act 4Health News:True Signs of Autism May Not Appear Until 1st Birthday 2Health News:MedCath Enters Definitive Agreement To Sell Heart Hospital of Austin 2Health News:Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research 2Health News:Attorney Joe Belluck Hails Department Of Defense For Increased Funding Of Mesothelioma Research 3
... fully adjustable, air-displacement pipette with a patented ... member of the Pipetman family, sharing many ... precision. We also added a number of ... Eight models cover the full range of ...
Developed specifically for the 5000/5500 ultrasound consoles....
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
... Hemispheric Sound Technology, multi-frequency, ... tiny transducer is very helpful ... proven to be a choice ... CBD scanning. Its high frequency ...
Medicine Products: